+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Ewing Sarcoma Pipeline Analysis and Outlook, 2019

  • ID: 4772536
  • Report
  • May 2019
  • Region: Global
  • 158 pages
  • VPA Research
1 of 3


  • Amgen Inc
  • Bristol-Myers Squibb Co
  • EntreChem SL
  • Ipsen SA
  • Merck & Co Inc
  • Oncoceutics Inc
  • MORE
Ewing Sarcoma pipeline

Ewing Sarcoma pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Ewing Sarcoma R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Ewing Sarcoma report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Ewing Sarcoma as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Ewing Sarcoma with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Ewing Sarcoma pipeline Profiled in detail

Key players actively participating in Ewing Sarcoma pipeline are profiled along with their R&D progress in Ewing Sarcoma treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Ewing Sarcoma pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Ewing Sarcoma treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Ewing Sarcoma pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Ewing Sarcoma pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Ewing Sarcoma pipeline study
  • All recent news and developments related to Ewing Sarcoma drugs are provided
Note: Product cover images may vary from those shown
2 of 3


  • Amgen Inc
  • Bristol-Myers Squibb Co
  • EntreChem SL
  • Ipsen SA
  • Merck & Co Inc
  • Oncoceutics Inc
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Ewing Sarcoma Disease Overview

3. Ewing Sarcoma Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Ewing Sarcoma Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Ewing Sarcoma Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Ewing Sarcoma companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Ewing Sarcoma Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • Amgen Inc
  • AntiCancer Inc
  • Astellas Pharma Inc
  • Atlanthera
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Cellectar Biosciences Inc
  • Eisai Co Ltd
  • EntreChem SL
  • Exelixis Inc
  • Genentech
  • Gradalis Inc Incyte Corp
  • Ipsen SA
  • Jiangsu Chia-Tai Tianqing Pharmaceutical
  • JSK Therapeutics Inc
  • MacroGenics Inc
  • MediaPharma SRL
  • Merck & Co Inc
  • Merrimack Pharmaceuticals Inc
  • Nanovalent Pharmaceuticals Inc
  • NantCell Inc
  • NantKwest Inc
  • Novartis AG
  • Oncoceutics Inc
  • Oncomatryx Biopharma SL
  • Oncternal Therapeutics Inc
  • Pfizer Inc
  • Pharma Mar SA
  • Salarius Pharmaceuticals LLC
  • Syndax Pharmaceuticals Inc
  • Syros Pharmaceuticals Inc
  • Tarveda Therapeutics Inc
  • Tesaro Inc
  • Tyme Inc
  • Y-mAbs Therapeutics Inc
Note: Product cover images may vary from those shown